Role of Crataegus oxyacantha (Hawthorn) on scopolamine induced memory deficit and monoamine mediated behaviour in rats

다국어 초록 (Multilingual Abstract)

Treatment of cognitive disorders is a challenging task in neurology since long time. Crataegus oxyacantha, also known as hawthorn belongs to family Rosaceae grown in colder areas and is one of the most widely used herb for the treatment of heart disorders. Traditionally Crataegus oxyacantha has also been used to treat Alzheimer disease, nervousness, stress, pain, and sleep disorders. In this study nootropic activity of petroleum ether, chloroform and methanol extract of Crataegus oxyacantha leaves was assessed using elevated plus maze model. Scopolamine (1 mg/kg) was used as amnesia inducing agent and piracetam (120 mg/kg) as standard nootropic drug. On the last day of the experiment, biochemical parameters like acetylcholinesterase, lipid peroxidase and superoxide dismutase were measured in brain homogenate. Effect of Crataegus oxyacantha on monoamines mediated behaviour was assessed through lithium induced head twitches and haloperidol induced catalepsy model in rats. Among all three extracts, methanol extract of Crataegus oxyacantha caused highest reduction in transfer latency time significantly as measured on 7th and 14th day and on 8th and 15th day on elevated maze and also decreased acetylcholinesterase and lipid peroxidase level and increased super oxide dismutase content as compared to scopolamine group. Methanol extract of Crataegus oxyacantha (200 mg/kg and 400 mg/kg) decreased number of head twitches and duration of catalepsy in rats significantly compared to vehicle treated group. So our study showed promising effect of Crataegus oxyacantha in enhancing learning and memory due to the presence of certain phytoconstituents.

참고문헌 (Reference)

1 ltoh J, "Utility of an elevated plusmaze for dissociation of amnesic and behavioural effects of drugs in mice" 194 : 71-76, 1991

2 Itoh J, "Utility of an elevated plus maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock" 101 : 27-33, 1990

3 Holden M, "Use of cholinesterase inhibitors in dementia" 8 : 89-96, 2002

4 Inglis F, "The tolerability and safety of cholinesterase inhibitors in the treatment of dementia" 127 : 45-63, 2002

5 Beninger RJ, "The role of dopamine in locomotor activity and learning" 287 : 173-196, 1983

6 Hasselmo ME, "The role of acetylcholine in learning and memory" 16 : 710-715, 2006

7 Ogren SO, "The role of 5-HT(1A)receptors in learning andmemory" 195 : 54-77, 2008

8 Bastianetto S, "The Ginkgo biloba extract, (EGb 761) protects hippocampal neurons against cell death induced by beta amyloid" 12 : 1882-1890, 2000

9 Yaffe K, "Subtype of mild cognitive impairment and progression to dementia and death" 22 : 312-319, 2006

10 Ying Y, "Study on the nootropic mechanism of ginsenoside Rb1 and Rg1-influene on mouse brain development" 29 : 241-245, 1994

11 Mozley LH, "Striatal dopamine transporters and cognitive functioning in healthy men and women" 158 : 1492-1499, 2001

12 Quartermain D, "Strength of scopolamine-induced amnesia as a function of time between training and testing" 50 : 300-310, 1988

13 Blandina P, "Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices" 256 : 341-347, 1991

14 Ebert U, "Scopolamine model of dementia: electroencephalogram findings and cognitive performance" 28 : 944-949, 1998

15 Ven Murthy MR, "Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: Ashwagandha" 10 : 238-246, 2010

16 Halliwell B, "Reactive oxygen species and the central nervous system" 59 : 1609-1623, 1992

17 Rehwald A, "Qualitative and quantitative reversed-phase high performance liquid chromatography of flavonoids in Crataegus leaves and flowers" 677 : 25-33, 1994

18 Caine ED, "Qualitative analysis of scopolamine-induced amnesia" 74 : 74-80, 1981

19 Al Makdessi S, "Protective effect of Crataegus oxyacantha against reperfusion arrhythmias after global no-flow ischemia in the rat heart" 94 : 71-77, 1999

20 Kim SH, "Procyanidins in crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta" 67 : 121-131, 2000

21 Jayalakshmi R, "Pretreatment with alcoholic extract of Crataegus oxycantha, (AEC) activates mitochondrial protection during isoproterenol–induced myocardial infarction in rats" 292 : 59-67, 2006

22 Balch PA, "Prescription for herbal healing" Avery 79-80, 2002

23 Tabach R, "Preclinical toxicological assessment of a phytotherapeutic product–CPV (based on dry extracts of Crataegus oxyacantha L., Passiflora incarnata L., and Valeriana officinalis L.)" 23 (23): 33-40, 2008

24 Doody RS, "Practice parameter: management of dementia, (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology" 56 : 1154-1166, 2001

25 Cui T, "Polyphenoliccontent and physiological activities of Chinese hawthorn" 70 : 2948-2956, 2006

26 Gouliaev AH, "Piracetam and other structurally related nootropics" 19 : 2-, 1994

27 Kostic DA, "Phenolic Content, and Antioxidant and Antimicrobial Activities of Crataegus oxyacantha L (Rosaceae) Fruit extract from Southeast Serbia" 11 : 117-124, 2012

28 OECD, "OECD Guideline for Testing of Chemicals: Acute Toxic Class Method, (No.423)" OECD 2002

29 Schindler U, "Nootropics drugs: Animal models for studying effect on cognition" 4 : 567-576, 1984

30 Une HD, "Nootropic and anxiolytic activity of saponins of Albizia leaves" 69 : 439-444, 2001

31 Singh HK, "Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monnieri Linn. (Bramhi)" 29 : S359-S365, 1997

32 Al Makdessi S, "Myocardial protection by pretreatment with Crataegus oxyacantha : an assessment by means of the release of lactate dehydrogenase by the ischemic and reperfused langendorff heart" 46 : 25-27, 1996

33 Budson AE, "Memory dysfunction" 352 : 692-699, 2005

34 Wielosz M, "Lithium-induced head twitches in rats" 31 : 410-411, 1979

35 Vibes J, "Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (Hawthorn) flower heads" 50 : 173-175, 1994

36 Al-Abdaly AIO, "Influence of crude extract of Hawthorn Crataegus oxyacantha on some physiological aspects in mature male rats exposed to hydrogen peroxide over load" 36 : 37-44, 2012

37 Khare CP, "Indian Herbal Remedies: Rational Westeren therapy, Ayurvedic and other traditional usage, botany, vol 238" Springer Verlage 2004

38 Pratico D, "Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer Amyloidosis" 21 : 4183-4187, 2001

39 Williams TI, "Increased levels of 4- hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease" 27 : 1094-1099, 2006

40 Elango C, "Immunomodulatory effect of Hawthorn extract in an experimental stroke model" 7 : 1-13, 2010

41 Walker AF, "Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial" 56 : 437-443, 2006

42 Abdul-Ghani AS, "Hypotensive effect of Crataegus oxyacantha" 25 : 216-220, 1987

43 Shanthi S, "Hypolipidemic activity of tincture of Crataegus in rats" 31 : 143-146, 1994

44 Kuzniak VJ, "Hawthorn, (Crataegusoxyacantha L.) Bark extract regulates antioxidant response element (ARE)- mediated enzyme expression Via Nrf2 pathway activation in normal hepatocyte cell line" 28 : 593-602, 2013

45 Zhang Z, "Hawthorn fruit is hypolipidemic in rabbits fed a high cholesterol" 132 : 5-10, 2002

46 Levites Y, "Green tea polyphenol (−)- epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydrpyridine-induced dopaminergic neurodegeneration" 78 : 1073-1082, 2001

47 Ferri CP, "Global prevalence of dementia: a Delphi consensus study" 366 : 2112-2117, 2005

48 Kono Y, "Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase" 186 : 189-195, 1978

49 Spencer JPE, "Flavonoids: modulators of brainfunction?" 99 : 60-77, 2008

50 Liu T, "Extraction optimization, purification and antioxidant activity of procyanidins from hawthorn (C. pinnatifidaBge. var. major) fruits" 119 : 1656-1662, 2010

51 Sharma AC, "Evaluation of learning and memory mechanisms employing elevated plus maze in rats and mice" 16 : 117-125, 1992

52 Arora A, "Evaluation of anxiolytic activity of aqueous and alcoholic extracts of leaves of Crataegus oxycantha in mice" 2 : 86-91, 2011

53 Ozyurek M, "Evaluation of antioxidant activity of Crataegus species collected from different regions of Turkey" 6 : 263-277, 2012

54 Jain SK, "Ethnobotany and research on medicinal plants in India In:Ethnobotany and search for new drugs" John Wiley and Sons 153-168, 1994

55 Staubli U, "Effects of 5-HT receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat" 75 : 2445-2452, 1995

56 Raina P, "Effectiveness of cholinesterase inhibitors and memantine for treating dementia. Evidence review for a clinical Practice guideline" 148 : 379-397, 2008

57 Lee SC, "Effect of red ginseng saponins and nootropic drugs on impaired acquisition of ethanol-treated rats in passive avoidance performance" 69 : 1-8, 2000

58 Nyback H, "Effect of piracetam on brain monoamine metabolism and serum prolactin levels in the rat" 61 : 235-238, 1979

59 Can OD, "Effect of hawthorn seed and pulp extracts on the central nervous system" 48 : 924-931, 2010

60 Long SR, "Effect of hawthorn (Crataegus oxycantha) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay" 13 : 643-650, 2006

61 Popping S, "Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes" 45 : 1157-1161, 1995

62 Jaiswal AK, "Effect of Shilajit on memory, anxiety and brain monoamines in rats" 24 : 12-17, 1992

63 Iyer MR, "Effect of Lawsonia inermis on memory and behaviour mediated via monoamine neurotransmitters" 30 : 181-185, 1998

64 Kumar A, "Effect of BR-16A (Mentat) a polyherbal formulation on drug-induced catalepsy in mice" 44 : 45-48, 2006

65 Hanus M, "Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders" 20 : 63-71, 2004

66 Reddy DS, "Differential anxiolytic effects neurosteroids in the mirrored chamber behavior test in mice" 752 : 61-71, 1997

67 Manyam BV, "Dementia in Ayurveda" 5 : 81-88, 1999

68 Veveris M, "Crataegus special extractWS®1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion" 74 : 1945-1955, 2004

69 Jayachandran KS, "Crataegus oxyacantha extract attenuates apoptotic incidence in myocardial ischemia-reperfusion injury by regulating Akt and Hif-1 signaling pathways" 56 : 526-531, 2010

70 Weikl A, "Crataegus Special ExtractWS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)" 114 : 291-296, 1996

71 Rai KS, "Clitoria ternatea enhances learning and memory– An experimental study on rats" 32 : 150-, 2000

72 Petkov VD, "Changes in the brain biogenic monoamines of rats, induced by piracetamand aniracetam" 10 : 6-15, 1984

73 Kasture SB, "Baclofen- induced catatonia:modification by serotonergic agents" 35 : 595-598, 1996

74 Ohkawa H, "Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction" 95 : 351-358, 1979

75 Łętowska AS, "Antioxidant activity of the phenolic compounds of hawthorn, pine and skullcap" 103 : 853-859, 2007

76 Bahorun T, "Antioxidant activities of Crataegus monogyna extracts" 60 : 323-328, 1994

77 Vijayan NA, "Anti-inflammatory and anti-apoptotic effects of Crataegus oxyacantha on isoproterenol-induced myocardial damage" 367 : 1-8, 2012

78 Xu H, "A study of the comparative effects of hawthorn fruit compound and simvastatin on lowering blood lipid levels" 37 : 903-908, 2009

79 Degenring FH, "A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries, (Crataegisan®) in the treatment of patients with congestive heart failure NYHA II" 10 : 363-369, 2003

80 Youdim KA, "A possible emerging role of phytochemicals in improving age-related neurological dysfunctions : a multiplicity of effects" 30 : 583-594, 2001

81 Ellman GL, "A new and rapid colorimetric determination of acetylcholinestrase activity" 7 : 88-95, 1961